Compliance Policy Guide Sec. 540.525 Scombrotoxin (Histamine)-Forming Fish and Fishery Products-Decomposition and Histamine; Availability, 73295-73296 [2021-28053]
Download as PDF
Federal Register / Vol. 86, No. 245 / Monday, December 27, 2021 / Notices
to comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C. 653A(b)(1)(A)
and (B); 42 U.S.C. 653A(g)(2)(A); 26
U.S.C. 3304(a)(16)(B); 42 U.S.C.
503(h)(1)(A); and 42 U.S.C.
653A(g)(2)(B).
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2021–28065 Filed 12–23–21; 8:45 am]
BILLING CODE 4184–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Children’s Bureau National
Youth in Transition Database (NYTD)
(OMB #0970–0340)
Children’s Bureau,
Administration for Children and
Families, HHS.
ACTION: Request for public comment.
AGENCY:
The Administration for
Children and Families (ACF) is
requesting a 3-year extension of the
National Youth in Transition Database
(NYTD) Youth Services Report and
Youth Outcomes Survey Data Collection
(OMB #0970–0340, expiration date 03/
31/2022). There are no changes
requested to the form.
DATES: Comments due within 60 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, ACF is soliciting
public comment on the specific aspects
of the information collection described
above.
ADDRESSES: You can obtain copies of the
proposed collection of information and
submit comments by emailing
infocollection@acf.hhs.gov. Identify all
requests by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
Description: The Foster Care
Independence Act of 1999 (42 U.S.C.
1305 et seq.) as amended by Public Law
106–169 requires state child welfare
agencies to collect and report to the ACF
SUMMARY:
73295
Children’s Bureau data on the
characteristics of youth receiving
independent living services and
information regarding their outcomes.
The regulation implementing NYTD,
listed in 45 CFR 1356.80, contains
standard data collection and reporting
requirements for states to meet the law’s
requirements. Additionally, the Family
First Prevention Services Act of 2017
(H.R. 253) further outlines the
expectation of the collection and
reporting of data and outcomes
regarding youth who are in receipt of
independent living services. ACF uses
the information collected under the
regulation to track independent living
services, assess the collective outcomes
of youth, and potentially to evaluate
state performance with regard to those
outcomes consistent with the law’s
mandate.
Respondents: State agencies that
administer the Chafee Foster Care
Program for Successful Transition to
Adulthood (Chafee program) and youth
served by these agencies.
ANNUAL BURDEN ESTIMATES FOR 2022–2024
Total
number of
respondents
Information collection title
State Data File .....................................................................
Youth Outcomes Survey ......................................................
Total
number of
responses per
respondent
52
47,000
Average
burden hours
per response
2
1
3916
.5
Total burden
hours for
2022–24
407,264
23,500
khammond on DSKJM1Z7X2PROD with NOTICES
Estimated Annual Burden Total ....................................
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: NYTD is authorized by
Public Law 106–169, enacted December
14, 1999. This public law establishes the
John H. Chafee Foster Care
Independence Program, now known as
Chafee program, at section 477 of the
VerDate Sep<11>2014
19:11 Dec 23, 2021
Jkt 256001
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2021–28058 Filed 12–23–21; 8:45 am]
BILLING CODE 4184–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–D–0367]
Compliance Policy Guide Sec. 540.525
Scombrotoxin (Histamine)-Forming
Fish and Fishery Products—
Decomposition and Histamine;
Availability
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or we) is
announcing the availability of a draft
SUMMARY:
PO 00000
135,755
7,833
143,588
Social Security Act. NYTD data is
collected pursuant to 45 CFR 1356.80.
AGENCY:
Annual
burden hours
Frm 00059
Fmt 4703
Sfmt 4703
Compliance Policy Guide entitled ‘‘Sec.
540.525 Scombrotoxin (Histamine)forming Fish and Fishery Products—
Decomposition and Histamine.’’ The
draft guidance, when finalized, will
replace existing guidance for FDA staff
on adulteration associated with
decomposition and histamine identified
during surveillance sampling and
testing of fish and fishery products
susceptible to histamine formation.
DATES: Submit either electronic or
written comments on the draft guidance
by February 25, 2022 to ensure that we
consider your comment on the draft
guidance before we begin work on the
final version of the guidance.
ADDRESSES: You may submit comments
on any guidance at any time as follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
E:\FR\FM\27DEN1.SGM
27DEN1
73296
Federal Register / Vol. 86, No. 245 / Monday, December 27, 2021 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2021–D–0367 for ‘‘Sec. 540.525
Scombrotoxin (Histamine)-forming Fish
and Fishery Products—Decomposition
and Histamine (CPG 7108.24).’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ We
will review this copy, including the
claimed confidential information, in our
consideration of comments. The second
copy, which will have the claimed
VerDate Sep<11>2014
19:11 Dec 23, 2021
Jkt 256001
confidential information redacted/
blacked out, will be available for public
viewing and posted on https://
www.regulations.gov. Submit both
copies to the Dockets Management Staff.
If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single
copies of the draft guidance to Division
of Seafood Safety (HFS–325), Center for
Food Safety and Applied Nutrition,
Food and Drug Administration, 5001
Campus Dr., College Park, MD 20740.
Send two self-addressed adhesive labels
to assist that office in processing your
request. See the SUPPLEMENTARY
INFORMATION section for electronic
access to the draft guidance.
FOR FURTHER INFORMATION CONTACT:
Steven Bloodgood, Division of Seafood
Safety (HFS–325), Center for Food
Safety and Applied Nutrition, Food and
Drug Administration, 5001 Campus Dr.,
College Park, MD 20740, 240–402–5316,
email: steven.bloodgood@fda.hhs.gov; or
Jessica Larkin, Center for Food Safety
and Applied Nutrition, Office of
Regulations and Policy (HFS–024), Food
and Drug Administration, 5001 Campus
Dr., College Park, MD 20740, 240–402–
2378.
SUPPLEMENTARY INFORMATION:
I. Background
Frm 00060
Fmt 4703
II. Paperwork Reduction Act of 1995
FDA tentatively concludes that this
draft guidance contains no collection of
information. Therefore, clearance by the
Office of Management and Budget under
the Paperwork Reduction Act of 1995 is
not required.
III. Electronic Access
Persons with access to the internet
may obtain the draft guidance at either
https://www.fda.gov/FoodGuidances or
https://www.regulations.gov. Use the
FDA website listed in the previous
sentence to find the most current
version of the guidance.
Dated: December 21, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021–28053 Filed 12–23–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–1252]
Panray Corp. Sub Ormont Drug and
Chemical Co., Inc., et al.; Proposal To
Withdraw Approval of Three New Drug
Applications; Opportunity for a
Hearing
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration’s (FDA or Agency)
Center for Drug Evaluation and Research
(CDER) is proposing to withdraw
approval of three new drug applications
(NDAs) and is announcing an
opportunity for the NDA holders to
SUMMARY:
We are announcing the availability of
a draft Compliance Policy Guide (CPG)
entitled ‘‘Sec. 540.525 Scombrotoxin
(Histamine)-forming Fish and Fishery
Products—Decomposition and
Histamine (CPG 7108.24).’’ This draft
PO 00000
CPG would update and replace existing
guidance for FDA staff on adulteration
associated with decomposition and
histamine identified during surveillance
sampling and testing of fish and fishery
products susceptible to scombrotoxin
(histamine) formation. The draft CPG
would revise FDA regulatory action
guidance for sensory analysis and/or
histamine levels in scombrotoxinforming fish and fishery products.
We are issuing the draft guidance
consistent with our good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on this topic. It does not establish any
rights for any person and is not binding
on FDA or the public. You can use an
alternate approach if it satisfies the
requirements of the applicable statutes
and regulations.
Sfmt 4703
E:\FR\FM\27DEN1.SGM
27DEN1
Agencies
[Federal Register Volume 86, Number 245 (Monday, December 27, 2021)]
[Notices]
[Pages 73295-73296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-28053]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-D-0367]
Compliance Policy Guide Sec. 540.525 Scombrotoxin (Histamine)-
Forming Fish and Fishery Products--Decomposition and Histamine;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is announcing the
availability of a draft Compliance Policy Guide entitled ``Sec. 540.525
Scombrotoxin (Histamine)-forming Fish and Fishery Products--
Decomposition and Histamine.'' The draft guidance, when finalized, will
replace existing guidance for FDA staff on adulteration associated with
decomposition and histamine identified during surveillance sampling and
testing of fish and fishery products susceptible to histamine
formation.
DATES: Submit either electronic or written comments on the draft
guidance by February 25, 2022 to ensure that we consider your comment
on the draft guidance before we begin work on the final version of the
guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically,
[[Page 73296]]
including attachments, to https://www.regulations.gov will be posted to
the docket unchanged. Because your comment will be made public, you are
solely responsible for ensuring that your comment does not include any
confidential information that you or a third party may not wish to be
posted, such as medical information, your or anyone else's Social
Security number, or confidential business information, such as a
manufacturing process. Please note that if you include your name,
contact information, or other information that identifies you in the
body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2021-D-0367 for ``Sec. 540.525 Scombrotoxin (Histamine)-forming
Fish and Fishery Products--Decomposition and Histamine (CPG 7108.24).''
Received comments will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For more information about FDA's posting of comments to public dockets,
see 80 FR 56469, September 18, 2015, or access the information at:
https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
Submit written requests for single copies of the draft guidance to
Division of Seafood Safety (HFS-325), Center for Food Safety and
Applied Nutrition, Food and Drug Administration, 5001 Campus Dr.,
College Park, MD 20740. Send two self-addressed adhesive labels to
assist that office in processing your request. See the SUPPLEMENTARY
INFORMATION section for electronic access to the draft guidance.
FOR FURTHER INFORMATION CONTACT: Steven Bloodgood, Division of Seafood
Safety (HFS-325), Center for Food Safety and Applied Nutrition, Food
and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-
402-5316, email: [email protected]; or Jessica Larkin,
Center for Food Safety and Applied Nutrition, Office of Regulations and
Policy (HFS-024), Food and Drug Administration, 5001 Campus Dr.,
College Park, MD 20740, 240-402-2378.
SUPPLEMENTARY INFORMATION:
I. Background
We are announcing the availability of a draft Compliance Policy
Guide (CPG) entitled ``Sec. 540.525 Scombrotoxin (Histamine)-forming
Fish and Fishery Products--Decomposition and Histamine (CPG 7108.24).''
This draft CPG would update and replace existing guidance for FDA staff
on adulteration associated with decomposition and histamine identified
during surveillance sampling and testing of fish and fishery products
susceptible to scombrotoxin (histamine) formation. The draft CPG would
revise FDA regulatory action guidance for sensory analysis and/or
histamine levels in scombrotoxin-forming fish and fishery products.
We are issuing the draft guidance consistent with our good guidance
practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on this topic. It
does not establish any rights for any person and is not binding on FDA
or the public. You can use an alternate approach if it satisfies the
requirements of the applicable statutes and regulations.
II. Paperwork Reduction Act of 1995
FDA tentatively concludes that this draft guidance contains no
collection of information. Therefore, clearance by the Office of
Management and Budget under the Paperwork Reduction Act of 1995 is not
required.
III. Electronic Access
Persons with access to the internet may obtain the draft guidance
at either https://www.fda.gov/FoodGuidances or https://www.regulations.gov. Use the FDA website listed in the previous
sentence to find the most current version of the guidance.
Dated: December 21, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-28053 Filed 12-23-21; 8:45 am]
BILLING CODE 4164-01-P